Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-17-002010
Filing Date
2017-05-19
Accepted
2017-05-19 11:27:01
Documents
1
Period of Report
2017-05-17

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 4010
  Complete submission text file 0001562180-17-002010.txt   5431
Mailing Address 400 TOTTEN POND ROAD SUITE 110 WALTHAM MA 02451
Business Address 400 TOTTEN POND ROAD SUITE 110 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Issuer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SYNDAX PHARMACEUTICALS, INC. 400 TOTTEN POND ROAD, SUITE 110 WALTHAM MA 02451
Business Address
Sledge George W. Jr. (Reporting) CIK: 0001601351 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37708 | Film No.: 17856863